The react study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage

HIGHLIGHTS

• who: Nicolas Bruder from the Department of Anesthesia and Critical Care, Hu00f4pital de la Timone, AixMarseille Universitu00e9, rue Stu2011Pierre, Marseille, France have published the Article: The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage, in the Journal: (JOURNAL) of 11/03/2020
• what: The REACT study is designed to assess the safety and efficacy of in preventing clinical deterioration due to DCI in patients with aSAH. The REACT study aims at assessing the benefit . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.